Ginny Orndorff 
Executive Director and Chief Executive Officer 

Ginny Orndorff joined CID4 in February 2015.  She has over 30 years of bioscience company management experience.  She is acting CEO of SixOne Solutions, LLC, and Claudin Technologies, two University of Colorado Medical School spin-off companies working on novel cancer drugs. Ginny founded Evolutionary Genomics of Longmont, CO and was its CEO for 10 years, continuing today on its board of directors. Prior to that, she was CEO of GenoPlex of Denver, CO. She also served as Director of Technology/Business Development for NeXstar of Boulder, CO, and Director of Biotechnology Programs at the Colorado Advanced Technology Institute. Ginny began her bioscience career as a lab supervisor at Genex in Gaithersburg, MD.  She received a Bachelor’s Degree in Biology from the University of California Santa Cruz, a Master’s Degree in Microbiology from California State University San Jose, and an MBA from Loyola College.

Richard C. Duke, Ph.D. 
Founder and Chief Scientific Officer 

Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with fifteen years of experience in building, financing, and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions. He is currently Co-scientific Founder, President and CEO of ApopLogic Pharmaceuticals. Dr. Duke is a Co-scientific Founder and former CEO, President and Director of GlobeImmune, Inc. and was involved in the formation of Sierra Neuropharmaceuticals where he was an initial Director. These Colorado-based companies have raised more than $150 million in financing and have multiple products in phase 1 and 2 human clinical trials. In addition to his entrepreneurial activities, Dr. Duke has over twenty-five years of experience in cutting-edge biomedical research and is a tenured faculty member in the Departments of Medicine (Medical Oncology) and Immunology at the University of Colorado Denver. Dr. Duke has provided independent 3rd-party research analysis in the life sciences sector to Janus Capital and to venture capital firms.